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Purpose: Extrathyroidal extension (ETE) of papillary thyroid carcinoma (PTC) is a risk factor for tumor
recurrence. By TNM Classiﬁcation (7th edition), differentiated thyroid carcinoma with ETE is designated
T3 (minimal invasion), T4a (extended invasion), or T4b (more extensive unresectable invasion), according
to the degree of tumor involvement. We subsequently focused our investigation on minimal ETE (MEE),
analyzing the clinicopathologic characteristics, recurrence rate, and recurrence-free survival (RFS) in this
setting.
Methods: A retrospective study was conducted, based on 332 patients undergoing thyroidectomy for PTC
between January 2005 and December 2006.
Results: The study population was stratiﬁed into two groups: PTC with MEE (103/332; 31.0%) and PTC
withoutMEE (229/332; 69.0%). In patientswith PTC,MEE correlatedwith gender, tumor size, multifocality,
lymph node (LN) metastasis, underlying Hashimoto’s thyroiditis, and the nature of the surgery. However,
no signiﬁcant intergroup differences were evident with respect to age, recurrence rate, and LNmetastasis.
In multivariate analysis, LN metastasis (odds ratio ¼ 2.273; 95% conﬁdence interval, 1.280e4.037) was
recognized as an independent correlate of mETE (p ¼ 0.005). However, recurrence-free survival did not
differ signiﬁcantly between the groups (p¼ 0.153), evenwhen further stratiﬁed by the presence or absence
of LN metastasis.
Conclusion: In patients with PTC, MEE does not impact RFS. Thus, appropriate surgical intervention and
postoperative follow up are mandatory in PTC, regardless of its extent.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Papillary thyroid carcinoma (PTC) is the most common type of
thyroid cancer and has an excellent prognosis, with a less than 10%
cancer-relatedmortality rate.1 Although it can be treated, it recurs in
10e30% of stage IeIII PTC patients.2 Extrathyroidal extension, one of
the known clinicopathologic factors predicting a poor prognosis, has
been classiﬁed into two grades, minimal extrathyroidal extension
(MEE, extension to the sternothyroid muscle or perithyroid soft tis-
sue) and massive extrathyroidal extension (extension to the subcu-
taneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal
nerve) according to the range of extension.3 Massive extension has: þ82 51 898 9427.
ciates Ltd. Published by Elsevier Ltbeen shown to be related to themortality rate and recurrence rate of
patients with PTC,4,5 whereas MEE was reported to not affect those
rates, particularly in those less than 45 years of age, suggesting that
the prognostic signiﬁcance might be different6,7.
The development and distribution of ultrasound to evaluate
thyroid nodules has made possible the discovery of untouchable
nodules; diagnosis of thyroid cancer has increased. However, ul-
trasound has caused much controversy regarding deﬁning the
proper range of extension for surgery in an asymptomatic patient
with low-risk thyroid cancer and an untouchable tumor.8 MEE re-
fers to pathological capsular invasion diagnosed post-operatively
based on histological ﬁndings, and extension to the strap muscle
or soft tissue discovered during surgery. Total thyroidectomy or
central lymph node dissection is often performed for MEE; how-
ever, recently, a more progressive approach known as ‘radioisotope
therapy’ has been the procedure of choice.d. All rights reserved.
Table 1
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ORIGINAL RESEARCHHence, the present study aimed to evaluate the prognostic sig-
niﬁcance of MEE, as well as its effect on cervical lymph node
recurrence and recurrence-free survival, by comparing and
analyzing the postoperative clinicopathologic characteristics of PTC
patients with or without MEE.Age 0.603
Mean age at diagnosis 47.67  12.62 44.14  11.40
<45 years 49 (47.6%) 116 (50.7%)
45 years 54 (52.4%) 113 (49.3%)
Gender 0.037
Male 17 (16.5%) 20 (8.7%)
Female 86 (83.5%) 209 (91.3%)
Tumor size 0.162
2 cm 85 (82.5%) 202 (88.2%)
>2 cm 18 (17.5%) 27 (11.8%)
Multifocality 0.001
Single 63 (61.2%) 181 (79.0%)
Multiple 40 (38.8%) 48 (21.0%)
Hashimoto thyroiditis 0.039
(þ) 13 (12.6%) 51 (22.3%)
(e) 90 (87.4%) 178 (77.7%)
Surgery <0.001
Total thyroidectomy 70 (68.0%) 105(45.9%)
Less than total
thyroidectomy
33 (32.0%) 124 (54.1%)
LNa metastasis <0.001
(þ) 57 (55.3%) 54 (23.6%)
(e) 46 (44.7%) 175 (76.4%)
RAIb ablation <0.001
(þ) 57 (55.3%) 46 (20.1%)
(e) 46 (44.7%) 183 (79.9%)2. Methods
A total of 332 patients diagnosed with postoperative PTC and who were fol-
lowed up from January 2005 to December 2006 at Busan Paik Hospital e Surgery,
except those with massive extension, were included in the present study. Patients
had undergone prophylactic ipsilateral lymph node dissection in total or partial
thyroidectomy with a median follow up of 62 months (range, 13e38 months). Based
on the ﬁnal diagnosis determining extension to the thyroid capsule and perithyr-
oidal soft tissue and the intraoperative manifestations describing extension to the
sternothyroid muscle, the patients were divided into two groups: those with and
without MEE. Additionally, the following data were recorded: census data such as
age and gender, oncologic data (including tumor size, multi-lesion, extrathyroidal
extension, cervical lymph node metastases and tumor staging), and clinical ﬁndings
such as local recurrence and distant metastasis. Recurrence was diagnosed based on
a signiﬁcant increase in thyroglobulin, cervical ultrasound, computed tomography
(CT), and positron emission tomography (PET), and ﬁne-needle aspiration cytology
(FNAC) was conducted on metastasis-suspicious lymph nodes for a deﬁnite diag-
nosis. The collection of patient data and retrospective review protocol were
approved by the Institutional Review Board at Inje University Busan Paik Hospital.
Statistical analysis was performed using the SPSS software, ver. 15.0 (SPSS Inc.,
Chicago, IL, USA), and chi-squared test and Fisher’s exact test for univariate analysis
and binary logistic regression for multivariate analysis. Recurrence-free survival was
calculated using the KaplaneMeier method, and survival curves were compared
through the log-rank test, using a signiﬁcance level of 0.05.Recurrence 0.102
(þ) 14 (13.6%) 18 (7.9%)
(e) 89 (86.4%) 211 (92.1%)
a LN ¼ lymph node.
b RAI: Radio-iodine.3. Results
3.1. Clinical characteristics
The median age of the 332 patients was 45 years (range, 15e45
years), and there were 103 patients (31.0%) with and 229 patients
(69.0%) without MEE at the time of surgery. The mean ages of the
two groups were 47.7 years (range, 22e75 years) and 44.1 years
(15e75 years), respectively. MEE was identiﬁed in 32.3% of patients
aged 45 and older, greater than the 29.7% of patients younger than
45 years, albeit with no signiﬁcance (p ¼ 0.603). The male: female
ratio was 1:8 (37 males [11.1%] and 295 females [88.9%]; p ¼ 0.037)
(Table 1).Table 2
Multivariate analysis of clinicopathologic factors affecting minimal extrathyroidal
extension (mETE).
Factors ORa 95% CIb P value
Gender
Female 1 e e
Male 0.853 0.391e1.862 0.690
Tumor size
<2 cm 1 e e
2 cm 0.859 0.427e1.726 0.669
Multifocality
Single 1 e e
Multiple 1.344 0.773e2.463 0.339
LNc metastasis
() 1 e e
(þ) 2.273 1.280e4.037 0.005
Hashimoto thyroiditis
(e) 1 e e
(þ) 0.609 0.293e1.262 0.182
a OR: odds ratio.
b CI: conﬁdence interval.
c LN: Lymph node.3.2. Pathological characteristics
The proportion of MEE increased as the tumor size increased to
2 cm or larger, but was not statistically signiﬁcant (17.5% vs. 11.8%,
respectively; p ¼ 0.162). The presence of multiple nodules was
more frequent in the group with MEE (45.5%) than in the group
without MEE (25.8%), and more extension was observed in the
group with multiple nodules, compared with the group with a
single nodule, with a signiﬁcant difference in the presence of MEE
(p ¼ 0.001). The accompanying frequency of PTC and Hashimoto’s
thyroiditis found in postoperative biopsy was higher in the group
without MEE (p ¼ 0.039); there were more patients with a total
thyroidectomy in the group with MEE (p < 0.001). Lymph node
metastasis was observed more frequently in the group with MEE
(p < 0.001), including extension up to the lateral cervical lymph
nodes. After surgery, radioisotope therapy was conducted in 31.0%
of all patients, and complete resection using a radioisotope was
performed more frequently in the group with MEE (p < 0.001).
According to multivariate analysis, positive lymph node metastasis,
compared with negative lymph node metastasis, was a signiﬁcant
independent factor for a higher risk of MEE (p ¼ 0.005) (Table 2).3.3. Recurrence and recurrence-free survival
After 62 months of follow up, recurrence was found in 32 cases
(9.6%): 14 (4.2%) in the group with MEE and 18 (5.4%) in the group
without MEE. Among the patients with recurrence, MEE was pre-
sented in 53.8%, a higher percentage than that among patients
without recurrence (29.7%), but there was no signiﬁcant difference
in the presence of MEE according to recurrence (p ¼ 0.102). Distant
metastasis was not observed, but all patients experienced cervical
lymph node recurrence: 6 and 26 cases in central and lateral cer-
vical lymph nodes, respectively. Lateral lymph node metastasis was
most frequent in the IV region, followed by the III þ IV and III
Fig. 1. Recurrence-free survival (RFS) between patients with and without minimal
extrathyroidal extension (MEE). RFS was not signiﬁcantly different in patients with and
without MEE (P ¼ 0.153).
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survival according to the presence of MEE (p ¼ 0.153) (Fig. 1), or
in recurrence-free survival between the groups with and without
MEE according to lymph node metastasis (p ¼ 0.993) (Fig. 2).4. Discussion
PTC, if properly treated, shows not only an excellent prognosis
but also complete healing in most cases.9,10 Among the factors
determining this excellent prognosis, extrathyroidal extension
has been highlighted. Extrathyroidal extension is observed in 5e
45% of patients with PTC.4 Extrathyroidal extension has been
suggested to be related to the increased risk of local recurrence
and the decreased survival rate; thus, extrathyroidal extension
might be a factor predicting poor prognosis.11 Additionally,
extrathyroidal extension has been reported to affect the survival
rate according to age, tumor size, lymph node metastasis, and
distant metastasis.12Fig. 2. A. Recurrence-free survival according to minimal extrathyroidal extension in 111 pa
extrathyroidal extension in 221 patients without lymph node metastasis.Extrathyroidal extension is divided into two grades: minimal
extrathyroidal extension to the thyroid capsule, sternothyroid mus-
cle, or perithyroid soft tissue, and massive extrathyroidal extension
to the subcutaneous soft tissue, larynx, esophagus, trachea, recurrent
laryngeal nerve, prevertebral fascia, mediastinal vessels, or carotid
arteries. because of the possibility of understaging, and the variation
in the outcomes of treatment according to the above classiﬁcation,
some have suggested that PTC treatment should consider MEE.
Extrathyroidal extension diagnosed pathologically is related to
lymph node metastasis, a positive margin, and vascular invasion;
thus, some authors have argued that extrathyroidal extension pro-
motes a poor prognosis.13 However, most studies have reported that
MEE does not affect tumor recurrence.14,15 In addition, no signiﬁcant
difference in recurrence-free survival between the two groups with
and without MEE has been reported.7
Thus, in the presence of MEE only, there was no difference in
local recurrence and recurrence-free survival between the two
groups. Additionally, when the two groupswere compared in terms
of recurrence-free survival based on the existence of lymph node
metastasis, no difference according the presence of MEE was
observed.
It has been reported that the risk of MEE is greater with a
larger tumor size in older patients.16 According to that study, the
mean tumor size was larger in the group with MEE than in the
group without MEE. Additionally, as the tumor became larger, the
frequency of MEE increased. Because that study did not examine
the change in tumor size in the same region, the thyroid anatomy
(length, width, and thickness) should be considered to identify
the presence of MEE related to tumor location and the change in
its size to identify the signiﬁcance of tumor size as a risk factor of
MEE. The frequency of MEE was higher in the group aged 45
years or older, albeit not signiﬁcantly. Ito et al.7 argued that there
was no prognostic signiﬁcance of MEE in all ages, as well as the
group.
Cervical lymph nodemetastasis of PTC is identiﬁed in 20e50% of
patients during diagnosis and surgery. Particularly, even for T1 or
T2 stage, such metastasis is diagnosed in almost 30% of patients;
thus, PTC is a signiﬁcant prognostic factor for local recurrence and
distant metastasis.17 Lymph node dissection must be performed if
there is no capsule or if lymph node metastasis reaches 87% in
extrathyroidal extension.18 Moreover, according to domestic
studies, extrathyroidal extension predicts a higher proportion of
cervical lymph node metastasis, and so total thyroidectomy or se-
lective central lymph node dissection should be considered.19 Thetients with lymph node metastasis. B. Recurrence-free survival according to minimal
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the multivariate analysis, only cervical lymph node metastasis was
an independent factor for an increased risk of extrathyroidal
extension (p ¼ 0.005). Lymph node metastasis was conﬁrmed to be
correlated with the presence of MEE; thus, more progressive
treatment such as total thyroidectomy or radioisotope therapy
should be performed when such metastasis, a prognostic factor of
thyroid carcinoma, is identiﬁed (Table 2).
In accordance with UICC p TNM 7th edition classiﬁcation,
extrathyroidal extension is divided into two grades, and MEE was
understaged as T3. Subsequently, some studies have argued that
MEE is unrelated to prognosis.6,13 MEE has increased the possi-
bility of discovering untouchable nodules and diagnosing thyroid
cancer due to the use of ultrasound to evaluate thyroid nodules.
Therefore, it might be necessary to deﬁne the proper range of
surgery and appropriate postoperative therapy in asymptomatic
patients with low-risk thyroid cancer and untouchable tumor and
those with extrathyroidal extension diagnosed pathologically. If
the tumor size is less than 4 cm or pathological lymph node
metastasis was not detected, pStage would be upstaged to Stage
III, resulting in overestimation. Therefore, upgrading PTC by using
MEE and the UICC staging system should be reconsidered.
In the present study, the proportion of MEE was higher in the
group who underwent total thyroidectomy, and the frequency of
less-than-total thyroidectomy was greater in the group without
MEE (p < 0.001).5. Conclusion
There was no signiﬁcant difference in recurrence or recurrence-
free survival between the groups with and without MME in pa-
tients with PTC. Although lymph node metastasis was an inde-
pendent factor for the increased risk of MEE, it did not affect
recurrence-free survival according to the presence of MEE. Due to
the limitations of slow progression of PTC and the short-term na-
ture of this study, a long-term large-scale study should be con-
ducted to conﬁrm our ﬁndings (Figs. 1 and 2).
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